Home   >  
Angiogenesis/Protein Tyrosine Kinase
  • Jak/Stat Pathway
  • Wnt/Stem Cell
  • Epigenetics

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
QL-1200186 Chemical Structure
BCP49631 QL-1200186 2848664-42-4
QL-1200186 is an orally active and selective TYK2 inhibitor.
Filgotinib maleate Chemical Structure
BCP49095 Filgotinib maleate 1802998-75-9
Filgotinib maleate is a potent and selective JAK1 inhibitor under investigation for the treatment of rheumatoid arthritis (RA) and Crohn's disease.
Solcitinib Chemical Structure
BCP23893 Solcitinib 1206163-45-2
Solcitinib is a Janus kinase 1 (JAK1) inhibitor. Solcitinib may be potential useful for treatment of psoriasis,systemic lupus erythematosus, ulcerative colitis.
Pacritinib citrate Chemical Structure
BCP48998 Pacritinib citrate 1228923-42-9
Pacritinib Citrate is the citrate salt form of pacritinib, an orally bioavailable inhibitor of Janus kinase 2 (JAK2), the JAK2 mutant JAK2V617F and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity.
Ruxolitinib racemic Chemical Structure
BCP25428 Ruxolitinib racemic 1160597-27-2
Ruxolitinib racemic is a Janus-associated kinase (JAK) inhibitor.
GDC-0214 Chemical Structure
BCP47996 GDC-0214 1831144-46-7
GDC0214 is a potent, selective inhalable and lung-restricted inhibitor of JAK1 with IC50 of 8.52 nM, displays 6.3/704/28 fold selectivity over JAK2/JAK3/TYK2.
JAK-IN-5 hydrochloride Chemical Structure
BCP48031 JAK-IN-5 hydrochloride 2751323-21-2
JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
SJ10542 Chemical Structure
BCP46974 SJ10542 SJ10542
SJ10542 is JAK2/3 PROTAC. SJ10542 displayed high selectivity over GSPT1 and other members of the JAK family and potency in patient-derived ALL cells containing both JAK2 fusions and CRLF2 rearrangements.
G5-7 Chemical Structure
BCP46781 G5-7 939681-36-4
G5-7 is an orally active JAK2 inhibitor, selectively inhibits JAK2-mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 has the potential for glioma study.
SC99 Chemical Structure
BCP46780 SC99 882290-02-0
SC99 is a selective inhibitor of JAK2-STAT3 activation.
123下一页末页共 99 条记录 1 / 10 页